🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Mara Cananzi

University of Padua

ORCID: 0000-0002-7177-2847

Also affiliated with Center for Digestive and Liver Diseases, Azienda Ospedale - Università Padova

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 3 papers. Top paper: “Efficacy and safety of odevixibat in patients with Alagille syndrome (ASSERT): a phase 3, double-blind, randomised, placebo-controlled trial”.

Efficacy and safety of odevixibat in patients with Alagille syndrome (ASSERT): a phase 3, double-blind, randomised, placebo-controlled trial

The Lancet. Gastroenterology & hepatology(2024)10.1016/s2468-1253(24)00074-8

N/A

1.0DataRank · unranked

42 citations

Madeleine Aumar, Alastair Baker, Ulrich Baumann, Philip Bufler, Mara Cananzi +22 more

Impact of Genotype, Serum Bile Acids, and Surgical Biliary Diversion on Native Liver Survival in FIC1 Deficiency

Hepatology(2021)10.1002/hep.31787

N/A

0DataRank · unranked

56 citations

Richard J. Thompson, Emmanuel Gonzalès, Irena Jankowska, Benjamin L. Shneider, Étienne Sokal +66 more

IFIH1 loss-of-function variants contribute to very early-onset inflammatory bowel disease

Human Genetics(2021)10.1007/s00439-021-02300-4

N/A

0DataRank · unranked

44 citations

Elizabeth Wohler, Antonio Marzollo, Davide Colavito, Jing You, Huie Jing +25 more